Search results
Sanofi (SNY) Q3 2022 Earnings Call Transcript
Motley Fool· 1 year agoImage source: The Motley Fool. Sanofi (NASDAQ: SNY)Q3 2022 Earnings CallOct 28, 2022, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call...
Biogen hires former Sanofi head Viehbacher as CEO
Reuters via Yahoo Finance· 1 year ago(Reuters) -Biogen Inc on Thursday tapped former Sanofi boss Christopher Viehbacher as its new chief executive, betting on an industry veteran to help the...
Biogen tabs veteran pharma leader Viehbacher as next CEO
Associated Press via Yahoo News· 1 year agoBiogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug...
5 Examples of Hostile Takeovers That Actually Worked
GOBankingRates via Yahoo Finance· 2 years agoSpeaking to contemporary headlines, JetBlue Airways is currently maneuvering a hostile takeover of competition Spirit Airlines for $3.6 billion. Only...
BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
Zacks via Yahoo Finance· 2 months agoBioMarin Pharmaceutical BMRN reported fourth-quarter 2023 adjusted earnings per share of 49 cents,...
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
Zacks via Yahoo Finance· 2 years agoBioMarin Pharmaceutical BMRN reported second-quarter 2022 adjusted earnings of 59 cents per share,...
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
Zacks via Yahoo Finance· 2 years agoBioMarin Pharmaceutical BMRN reported adjusted earnings of 45 cents per share in third-quarter 2022,...
BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut
Zacks via Yahoo Finance· 6 months agoBioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company...
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
Zacks via Yahoo Finance· 2 years agoThe FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for...
BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down
Zacks via Yahoo Finance· 1 year agoBioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for...